Panama - İngilizce - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

winthrop pharmaceuticals de colombia s.a. - hedera helix (hederacósido c) - hedera helix (hederacósido c)....39.5mg de extracto seco

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - hedera helix, quantity: 2 mg/ml (equivalent: hedera helix, qty 12.5 mg/ml; equivalent: emetine, qty 2 mg/g) - oral liquid - excipient ingredients: citric acid; glycerol; hyetellose; potassium sorbate; purified water; sodium benzoate; sorbitol solution (70 per cent) (non-crystallising); flavour - expectorant/clear respiratory tract mucous ; decrease/reduce/relieve cough

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; calcium sulfate dihydrate; sodium bicarbonate; pregelatinised maize starch - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; sodium bicarbonate; calcium sulfate dihydrate; pregelatinised maize starch - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; calcium sulfate dihydrate; pregelatinised maize starch; sodium stearylfumarate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

helix pharmaceuticals pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: calcium sulfate dihydrate; pregelatinised maize starch; sodium stearylfumarate; sodium bicarbonate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 1000 [iu] - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection - helixate nexgen is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 250 [iu] - injection with diluent - 250 iu - active: octocog alfa 250 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection - helixate nexgen is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 500 [iu] - injection with diluent - 500 iu - active: octocog alfa 500 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection - helixate nexgen is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 2000 [iu] - injection with diluent - 2000 iu - active: octocog alfa 2000 [iu] excipient: calcium chloride glycine histidine polysorbate 80 sodium chloride sucrose water for injection - helixate nexgen is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.